Arm 1 for Stargardt Disease
This trial will test whether injecting stem cells derived from a patient's own bone marrow can help treat damage to the retina or optic nerve.
- Stargardt Disease
- Retinal Disease
- Optic Atrophy
- Low Vision
- Optic Neuropathy
- Ischemic Optic Neuropathy
- Leber Optic Neuropathy
- Night Blindness
- Partial Vision Loss
- Macular Abnormality
- Retinal Atrophy
- Retinal Disorders
- Retinitis Pigmentosa
- Age-Related Macular Degeneration
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this examination currently enrolling participants?
"Per the clinicaltrials.gov listing, recruitment is still open for this experiment that was initially posted on January 1st 2016 and revised lastly in November 25th 2022."
To what extent is participation in this medical experiment limited?
"Affirmative. According to the information published on clinicaltrials.gov, this medical trial is currently recruiting participants and was initially posted on New Year's Day 2016 before being updated in November 2022. The research team are hoping to enrol 500 patients from two different sites."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- MD Stem Cells: < 24 hours
- Medcare Orthopaedics & Spine Hospital: < 24 hours
Average response time
- < 2 Days